JP2025111457A5 - - Google Patents
Info
- Publication number
- JP2025111457A5 JP2025111457A5 JP2025052993A JP2025052993A JP2025111457A5 JP 2025111457 A5 JP2025111457 A5 JP 2025111457A5 JP 2025052993 A JP2025052993 A JP 2025052993A JP 2025052993 A JP2025052993 A JP 2025052993A JP 2025111457 A5 JP2025111457 A5 JP 2025111457A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- spik
- antibody
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962871565P | 2019-07-08 | 2019-07-08 | |
| US62/871,565 | 2019-07-08 | ||
| JP2022500004A JP7658946B2 (ja) | 2019-07-08 | 2020-07-08 | カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法 |
| PCT/US2020/041228 WO2021007338A1 (en) | 2019-07-08 | 2020-07-08 | Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022500004A Division JP7658946B2 (ja) | 2019-07-08 | 2020-07-08 | カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025111457A JP2025111457A (ja) | 2025-07-30 |
| JP2025111457A5 true JP2025111457A5 (https=) | 2025-10-30 |
Family
ID=71944318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022500004A Active JP7658946B2 (ja) | 2019-07-08 | 2020-07-08 | カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法 |
| JP2025052993A Pending JP2025111457A (ja) | 2019-07-08 | 2025-03-27 | カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022500004A Active JP7658946B2 (ja) | 2019-07-08 | 2020-07-08 | カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12377162B2 (https=) |
| EP (1) | EP3996816A1 (https=) |
| JP (2) | JP7658946B2 (https=) |
| CN (2) | CN114174341A (https=) |
| CA (1) | CA3145301A1 (https=) |
| WO (1) | WO2021007338A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12180301B2 (en) | 2018-03-06 | 2024-12-31 | Imcare Biotech, Llc | Serine protease inhibitor kazal (SPIK) compositions and methods |
| US12377162B2 (en) | 2019-07-08 | 2025-08-05 | Imcare Biotech, Llc | Anti-serine protease inhibitor kazal (SPIK) antibodies, immunoconjugates, and methods of use |
| EP4028132A1 (en) * | 2019-09-11 | 2022-07-20 | Imcare Biotech, LLC | Epitopes of anti-serine protease inhibitor kazal (spik) antibodies |
| WO2024006520A1 (en) * | 2022-06-30 | 2024-01-04 | Allonnia, Llc | Per- and polyfluorinated alkyl compound (pfas) binding proteins and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| EP0731106B1 (en) | 1993-10-01 | 2004-11-17 | Teikoku Hormone Mfg. Co., Ltd. | Dolastatin derivatives |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6248564B1 (en) | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| CA2467242A1 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| US8193328B2 (en) | 2005-09-08 | 2012-06-05 | Philadelphia Health & Education Corporation | Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents |
| CA2703140A1 (en) | 2007-10-25 | 2009-04-30 | Viventia Biotech Inc. | Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof |
| RU2583270C2 (ru) | 2009-04-01 | 2016-05-10 | Дженентек, Инк. | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| WO2011102999A2 (en) | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Spink1 targeted therapy |
| WO2012078752A2 (en) * | 2010-12-09 | 2012-06-14 | Philadelphia Health & Education Corporation D/B/A | Serine protease inhibitor kazal antibodies |
| EP2699603B1 (en) | 2011-04-19 | 2016-03-02 | The United States of America As Represented by the Secretary Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| CA2898472C (en) * | 2013-02-15 | 2023-03-07 | Immunomedics, Inc. | Chimeric and humanized anti-histone antibodies |
| WO2015164757A1 (en) | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| BR112018070097A2 (pt) | 2016-03-29 | 2019-02-12 | Obi Pharma, Inc. | anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos |
| EA202091540A1 (ru) | 2017-12-22 | 2021-03-22 | Джаунс Терапьютикс, Инк. | Антитела к lilrb2 |
| US12180301B2 (en) * | 2018-03-06 | 2024-12-31 | Imcare Biotech, Llc | Serine protease inhibitor kazal (SPIK) compositions and methods |
| CN109678950B (zh) * | 2019-01-08 | 2022-05-10 | 灏灵赛奥（天津）生物科技有限公司 | spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品 |
| US12377162B2 (en) | 2019-07-08 | 2025-08-05 | Imcare Biotech, Llc | Anti-serine protease inhibitor kazal (SPIK) antibodies, immunoconjugates, and methods of use |
| EP4028132A1 (en) * | 2019-09-11 | 2022-07-20 | Imcare Biotech, LLC | Epitopes of anti-serine protease inhibitor kazal (spik) antibodies |
| JP7713956B2 (ja) | 2020-04-15 | 2025-07-28 | ボイジャー セラピューティクス インコーポレイテッド | タウ結合化合物 |
-
2020
- 2020-07-08 US US17/625,693 patent/US12377162B2/en active Active
- 2020-07-08 CA CA3145301A patent/CA3145301A1/en active Pending
- 2020-07-08 CN CN202080054708.9A patent/CN114174341A/zh active Pending
- 2020-07-08 EP EP20750919.1A patent/EP3996816A1/en active Pending
- 2020-07-08 CN CN202510175468.2A patent/CN119874926A/zh active Pending
- 2020-07-08 JP JP2022500004A patent/JP7658946B2/ja active Active
- 2020-07-08 WO PCT/US2020/041228 patent/WO2021007338A1/en not_active Ceased
-
2025
- 2025-03-27 JP JP2025052993A patent/JP2025111457A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025111457A5 (https=) | ||
| JP2022540079A5 (https=) | ||
| JP2020526478A5 (https=) | ||
| JP2009541204A5 (https=) | ||
| JP2022525377A5 (https=) | ||
| RU2010117018A (ru) | Антитела к gdf8 и их применения | |
| JP2007527406A5 (https=) | ||
| JP6081699B2 (ja) | Ｉｌ−２８ｂの分析方法 | |
| JP2016500659A5 (https=) | ||
| JP2020516603A5 (https=) | ||
| JP2021501579A5 (https=) | ||
| JP2018525320A5 (https=) | ||
| JP2012511026A5 (https=) | ||
| JP2018501483A (ja) | 干渉を減少させるための方法 | |
| JP2021515597A5 (https=) | ||
| JP2018520127A5 (https=) | ||
| WO2004081569A1 (ja) | 腫瘍マーカーとしてのｎ１，ｎ１２－ジアセチルスペルミン | |
| RU2019132201A (ru) | Антитела к человеческому эритроферрону и их применение | |
| JP2021155416A5 (https=) | ||
| JP2019138777A5 (https=) | ||
| WO2022023461A1 (en) | Improved epitope for detecting and/or quantifying autoantibodies against alpha-fetoprotein | |
| US20240118278A1 (en) | Hbv diagnostic, prognostic, and therapeutic methods and products | |
| JP2018524270A5 (https=) | ||
| JP2018520366A5 (https=) | ||
| JP2022547574A5 (https=) |